Trial · NCT05168813
Adverse events1,920
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,920
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Part A (Open-label): Study Group 1 | 0 | 558 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | Part A (Open Label): Study Group 2 | 0 | 692 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | Part A (Open-label): Study Group 3 | 0 | 99 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | Part A (Open-label): Study Group 4 | 0 | 142 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | Part B (Blinded): mRNA-1273 at Month 6 | 1 | 1,323 | 1 |
| other | Anaemia | Blood and lymphatic system disorders | Part B (Blinded): mRNA-1273.222 at Month 6 | 0 | 89 | 0 |
| other | Iron deficiency anaemia | Blood and lymphatic system disorders | Part A (Open-label): Study Group 1 | 1 | 558 | 1 |
| other | Iron deficiency anaemia | Blood and lymphatic system disorders | Part A (Open Label): Study Group 2 | 0 | 692 | 0 |
| other | Iron deficiency anaemia | Blood and lymphatic system disorders | Part A (Open-label): Study Group 3 | 0 | 99 | 0 |
| other | Iron deficiency anaemia | Blood and lymphatic system disorders | Part A (Open-label): Study Group 4 | 0 | 142 | 0 |
| other | Iron deficiency anaemia | Blood and lymphatic system disorders | Part B (Blinded): mRNA-1273 at Month 6 | 0 | 1,323 | 0 |
| other | Iron deficiency anaemia | Blood and lymphatic system disorders | Part B (Blinded): mRNA-1273.222 at Month 6 | 0 | 89 | 0 |
| other | Lymphadenopathy | Blood and lymphatic system disorders | Part A (Open-label): Study Group 1 | 1 | 558 | 1 |
| other | Lymphadenopathy | Blood and lymphatic system disorders | Part A (Open Label): Study Group 2 | 0 | 692 | 0 |
| other | Lymphadenopathy | Blood and lymphatic system disorders | Part A (Open-label): Study Group 3 | 0 | 99 | 0 |
| other | Lymphadenopathy | Blood and lymphatic system disorders | Part A (Open-label): Study Group 4 | 0 | 142 | 0 |
| other | Lymphadenopathy | Blood and lymphatic system disorders | Part B (Blinded): mRNA-1273 at Month 6 | 0 | 1,323 | 0 |
| other | Lymphadenopathy | Blood and lymphatic system disorders | Part B (Blinded): mRNA-1273.222 at Month 6 | 0 | 89 | 0 |
| other | Lymphadenopathy (Solicited) | Blood and lymphatic system disorders | Part A (Open-label): Study Group 1 | 64 | 558 | 70 |
| other | Lymphadenopathy (Solicited) | Blood and lymphatic system disorders | Part A (Open Label): Study Group 2 | 34 | 692 | 34 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05168813/events